TLDR
- 21Shares has officially filed a proposal with the SEC for a spot Injective ETF.
- The ETF aims to offer investors direct exposure to INJ through physical token custody.
- Injective’s official X account shared the ETF filing, increasing market visibility and interest.
- INJ price remained stable above $8.00 after briefly dipping to $7.80 earlier in October.
- The Injective blockchain continues expanding through strategic partnerships and ecosystem development.
21Shares has officially filed with the SEC for a new spot Injective ETF, aiming to offer direct exposure to INJ. The filing arrives as Injective continues gaining traction in institutional and DeFi markets, backed by strong infrastructure. INJ price hovered near $8.75 following the news, as bulls held firm despite recent market pressure.
21Shares Advances Injective ETF Plans
21Shares submitted its proposed Injective ETF to the U.S. Securities and Exchange Commission early this week. The ETF will hold physical INJ tokens in cold storage to provide direct price exposure. This structure aligns with the approved spot ETFs for Bitcoin and Ethereum.
🚨 BREAKING: 21Shares just filed for a new $INJ ETF.
This is a major signal of growing institutional interest, making $INJ one of the few digital assets with multiple ETF products in progress.@21Shares is among the world’s largest exchange traded product issuers. pic.twitter.com/xjWSZJVmsT
— Injective 🥷 (@injective) October 20, 2025
The company shared the news on Injective’s official X account, boosting market visibility and token sentiment. Market watchers noted that the Injective ETF represents rising interest in Layer 1 blockchains. Previously, Canary Capital had filed for a similar INJ ETF in July.
The 21Shares Injective ETF marks another step toward institutional integration of DeFi-focused digital assets. “This ETF will offer exposure to INJ via secure cold storage,” stated the official filing. With SEC reviews underway, industry participants anticipate broader access to Injective via regulated investment vehicles.
Injective’s Market Position Strengthens
Injective, a high-performance Layer 1 blockchain, is gaining attention for its institutional partnerships and rapid technical development. The network processes over 25,000 transactions per second using delegated proof-of-stake (DPoS) consensus. This architecture supports scalability and low-latency trading for DeFi markets.
Its roadmap includes native Ethereum Virtual Machine compatibility and pre-IPO market tools, supported by strong partners like Google Cloud and BitGo. Recent developments include the first meeting of the Injective Council, focused on advancing governance and strategic goals. The Injective ETF filing aligns with these broader expansion efforts.
Token liquidity and platform adoption continue to rise amid increased DeFi and real-world asset integration. The Injective ETF further enhances its standing among top blockchain networks. As institutional players explore this asset, long-term demand for INJ could increase.
INJ Price Holds Amid ETF Buzz
INJ traded around $8.75 as of Monday, showing stability despite broader crypto volatility and recent dips. Prices had dropped to $7.80 on October 17 but recovered as bullish interest returned. Traders aim to maintain support above $8.00, with positive momentum from ETF-related news.
INJ remains down from its March high of $52.75 and December peak near $35. Yet, optimism surrounds ETF-driven accumulation and treasury strategies. For example, Pineapple Financial recently allocated $100 million in digital assets, including INJ.
While the Injective ETF news hasn’t sparked a major rally, sentiment remains strong across crypto markets. The SEC’s decisions on crypto ETFs could shape short-term price movements. Nevertheless, the Injective ETF proposal reinforces growing institutional confidence in the asset.
